Type 2-skewed atopic features in pediatric alopecia areata: evidence, candidate biomarkers, and treatment considerations in the JAK inhibitor era
Year: 2026
Type: article
Abstract: Treatment options for pediatric alopecia areata (AA) are expanding, but treatment selection remains guided mainly by clinical severity, with limited biologic stratification. The established AA model centers on loss of hair follicle immune privilege, cytotoxic T-cell infiltration, interferon- γ (IFN- γ )/interleukin-15 (IL-15) signaling, and downstream Janus kinase–signal transducer and activator of transcription (JAK-STAT) activation. Some children also have atopic dermatitis (AD), asthma, or allergic rhinitis, together with elevated immunoglobulin E (IgE) or eosinophilia. We examine whether these clinical features have a counterpart in AA tissue and assess the directness of the pediatric evidence. Studies of lesional scalp in predominantly adult or mixed-age cohorts identify type 2-associated signals alongside the canonical cytotoxic axis, but do not establish a distinct pediatric endotype. Circulating IgE and eosinophils may reflect concomitant atopy; neither has been validated to diagnose AA, predict its course, or select treatment. JAK inhibitors remain the principal AA-directed systemic option when age, indication, severity, and monitoring requirements align. Dupilumab blocks the interleukin-4 receptor α (IL-4R α ) and may be considered for an independently indicated type 2 comorbidity, while its effect on AA in children remains exploratory. Prospective pediatric studies linking clinical atopy, lesional immune signatures, accessible markers, and treatment outcomes are needed before this proposed framework can guide care.
Source: Frontiers in Pediatrics
Institution: China-Japan Friendship Hospital
Language: English
Topic: Hair Growth and Disorders
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7237202004
